Drugs / HFO MDI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05850494 | May → Aug 2023 | asthma | AstraZeneca | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFO MDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05850494 ↗ |